Catalent Applied Drug Delivery Institute Discuss Collaborative Approach Of Non-Invasive Macromolecule Delivery Consortium At First Public Meeting

Somerset, N.J. – January 26, 2015 — The Catalent Applied Drug Delivery Institute (CADDI) today announced that members of its Non-Invasive Macromolecule Delivery Consortium (NMDC) will discuss the collaborative approach of the Institute at the upcoming Drug Delivery Partnerships Conference, taking place at Boca Raton Resort & Club, Florida, from the 28th to 30th of January 2015.

The panel session, entitled “To Begin a New Adventure: Engaging Academic and Industrial Expertise in Non-invasive Delivery of Macromolecules,” takes place on Thursday, January 29th at 4.30 pm and will be chaired by NMDC Chairman, Dr. Randy Mrsny. Also on the panel will be Professor Justin Hanes of John Hopkins University, who is the Academic Co-Chair of the NMDC’s Ocular Working Group, Ralph Niven from Novartis, Industry Co-Chair of the NMDC’s Pulmonary/Nasal Working Group, Siddhesh Patil from Takeda, who is Industry Co-Chair of the NMDC’s Oral Working Group, and Mark Tomai from 3M’s Drug Delivery Systems Division.

Also speaking at the event is Cornell Stamoran, CADDI Board Member and Vice President, Corporate Strategy at Catalent. He will be part of a panel session on Friday, January 30th at 9.45 am, entitled “Patient Adherence Trends, Engagement Strategies and Innovative Solutions to Enhance Patient Compliance and Deliver Customer Value – a Discussion with Leading Providers of innovative Patient Adherence Solutions,” as well as giving a presentation at 3.00 pm on the same day, “What have We Learned from the Drug Delivery Landscape Survey that will Shape the Future?”.

Established in 2012, the Catalent Applied Drug Delivery Institute employs a multi-tiered approach to accelerate the adoption of advanced drug delivery technologies through industry and academic collaboration, research, education, and the sharing of information.

The Institute launched the NMDC in June 2014, with a gathering of around 80 drug delivery experts who discussed the challenges of delivery macromolecules via the oral, pulmonary & nasal, ocular and transdermal routes. The Catalent Institute’s role is focused on building a community of practice, matchmaking drug delivery experts and companies, and fostering opportunities for research to advance alternate methods of delivering large molecules resulting in better patient outcomes.

For more details on the Catalent Institute, visit and follow the Catalent Institute on Twitter: @DrugDeliveryIns

About Catalent Applied Drug Delivery Institute

Catalent’s Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments and foster industry collaboration on major issues pertaining to drug development, formulation and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies.

About Catalent

Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit 

 More products. Better treatments. Reliably supplied.™